These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4149356)

  • 21. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and azo-link cleavage of salazopyrine in man.
    Lewkonia RM; Schröder H; Evans DA
    Gut; 1973 May; 14(5):426-7. PubMed ID: 4146086
    [No Abstract]   [Full Text] [Related]  

  • 23. [Salazosulfapyridine or 5-aminosalicylic acid].
    Terpstra JJ
    Ned Tijdschr Geneeskd; 1987 Aug; 131(32):1409-10. PubMed ID: 2889151
    [No Abstract]   [Full Text] [Related]  

  • 24. [Early prognosis of hormone refractoriness development in inflammatory intestinal diseases].
    Baryshnikov EN
    Eksp Klin Gastroenterol; 2007; (5):138-44. PubMed ID: 18389610
    [No Abstract]   [Full Text] [Related]  

  • 25. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
    van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH
    Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
    Schölmerich J
    Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous formation of immunogenic conjugates by 5-aminosalicylic acid--a biotransformation product of salicylazosulfapyridine.
    Cîrstea M; Suhaciu G; Cîrje M
    Physiologie; 1983; 20(3):161-7. PubMed ID: 6139832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salazopyrin metabolism in ulcerative colitis.
    Das KM; Eastwood MA; Macmanus JP; Sircus W
    Gut; 1972 Oct; 13(10):840. PubMed ID: 4404480
    [No Abstract]   [Full Text] [Related]  

  • 29. [The role of cytokines in the pathogenesis of inflammatory intestinal diseases].
    Hommes DW; van Dullemen H; Radema SA; Tytgat GN; van Deventer SJ
    Ned Tijdschr Geneeskd; 1994 Dec; 138(49):2427-32. PubMed ID: 7997297
    [No Abstract]   [Full Text] [Related]  

  • 30. A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals.
    Del Soldato P; Campieri M; Brignola C; Bazzocchi G; Gionchetti P; Lanfranchi GA; Tamba M
    Gastroenterology; 1985 Nov; 89(5):1215-6. PubMed ID: 2864302
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of ulcerative colitis with salicylazosulfapyridine].
    ROTA L
    Riforma Med; 1953 May; 67(18):501-2. PubMed ID: 13089374
    [No Abstract]   [Full Text] [Related]  

  • 32. Response of ulcerative colitis to therapy with salicylazosulfapyridine.
    MORRISON LM
    J Am Med Assoc; 1953 Jan; 151(5):366-8. PubMed ID: 13010999
    [No Abstract]   [Full Text] [Related]  

  • 33. Results of treatment of ulcerative colitis with salicylazosulfapyridine.
    MORRISON LM
    Gastroenterology; 1952 May; 21(1):133-8. PubMed ID: 14926821
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [40 years of salazosulfapyridine. Is end in sight?].
    van Hees PA; van Tongeren JH
    Ned Tijdschr Geneeskd; 1982 Oct; 126(44):2014-8. PubMed ID: 6129576
    [No Abstract]   [Full Text] [Related]  

  • 37. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.
    MOERTEL CG; BARGEN JA
    Ann Intern Med; 1959 Nov; 51():879-89. PubMed ID: 14423204
    [No Abstract]   [Full Text] [Related]  

  • 38. [Possible mechanism of action of Azulfidine/Salazopyrin].
    Campbell DE
    Z Gastroenterol Verh; 1981 Jun; 19():15-20. PubMed ID: 6168126
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical aspects of ulcerative colitis in mainland China.
    Zheng JJ
    Chin J Dig Dis; 2006; 7(2):71-5. PubMed ID: 16643333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.